Statistics from Altmetric.com
MEDLINE (1966 to July 2004), Cochrane Database of Systematic Reviews, plus hand search of reference lists.
Study selection and analysis:
The review included placebo controlled, double blind randomised controlled trials (RCTs) of drug therapy for the neuropsychiatric symptoms of dementia, and meta-analyses of such RCTs. Studies of drugs not available in the US or no longer in clinical use and studies of depressive symptoms alone were excluded.
Atypical antipsychotics: six RCTs, all of risperidone or olanzapine, met inclusion criteria. Four RCTs (1380 people) found that antipsychotic treatment improved neuropsychiatric symptoms compared with placebo (see http://www.ebmentalhealth.com/supplemental for table). However, improvements were often small, and risperidone and olanzapine have been reported to increase cerebrovascular events in people with dementia. Typical antipsychotics: two meta-analyses met inclusion criteria. One meta-analysis (seven RCTs; 252 people) found that typical antipsychotics reduced neuropsychiatric symptoms more than …
The table is available as a downloadable PDF (printer friendly file).
If you do not have Adobe Reader installed on your computer,
you can download this free-of-charge, please Click here
Files in this Data Supplement:
- [view PDF] - Placebo controlled RCTs of atypical antipsychotics for the neuropsychiatric symptoms of dementia.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.